Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vasko Gulevski

Neurology Freehold, NJ Medical Doctor

NPI 1528011517 CMS profile 114513

77-55 Schanck Road,, Suite B11, Freehold, NJ 07728

Open in the dashboard

General payments

$23,682

1,598 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vasko Gulevski of Freehold, NJ is reported in the CMS Open Payments database as having received $23,682 across 1,598 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,388 261
2024 General $3,254 261
2023 General $8,075 286
2022 General $2,762 240
2021 General $2,683 235
2020 General $1,544 135
2019 General $1,976 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vasko Gulevski
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Vasko Gulevski were reported at $3,388. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Vasko Gulevski Neurology median Middle half National median
2019 $1,976 $474 $118–$2,177 $163
2020 $1,544 $367 $82–$2,309 $114
2021 $2,683 $438 $104–$2,547 $132
2022 $2,762 $442 $103–$2,388 $149
2023 $8,075 $464 $119–$2,312 $160
2024 $3,254 $468 $119–$2,323 $164
2025 $3,388 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $7,768 300 payments
  2. Novartis Pharmaceuticals Corporation $1,537 146 payments
  3. Pfizer Inc. $1,484 143 payments
  4. Teva Pharmaceuticals USA, Inc. $1,480 140 payments
  5. EMD Serono, Inc. $1,442 99 payments
  6. Lilly USA, LLC $1,093 70 payments
  7. Biogen, Inc. $1,022 78 payments
  8. Supernus Pharmaceuticals, Inc. $505 44 payments
  9. Allergan Inc. $485 56 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $466 57 payments
  11. Other $6,399 465 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,682 1,583 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,938 8 payments
  3. Education $62 7 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $7,010 222 payments
  2. QULIPTA $6,900 199 payments
  3. NURTEC ODT Pain $1,290 126 payments
  4. ZAVZPRET $1,228 121 payments
  5. NURTEC ODT Primary Care $709 80 payments
  6. KESIMPTA $597 62 payments
  7. EMGALITY $582 43 payments
  8. AIMOVIG $519 51 payments
  9. Austedo XR $512 42 payments
  10. VUMERITY $507 37 payments
  11. Other $12,431 960 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

2,213

Median for Neurology: 833

Drug cost

$1,607,111

Median for Neurology: $202,670

Branded share of claims

29.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ultomiris Ravulizumab-Cwvz Brand 17 $1,172,779
Qulipta Atogepant Brand 91 $104,328
Ubrelvy Ubrogepant Brand 54 $85,861
Nurtec Odt Rimegepant Sulfate Brand 24 $50,510
Rexulti Brexpiprazole Brand 15 $33,253
Aimovig Autoinjector Erenumab-Aooe Brand 23 $20,005
Emgality Pen Galcanezumab-Gnlm Brand 28 $18,471
Fycompa Perampanel Brand 11 $15,590
Briviact Brivaracetam Brand 12 $12,883
Keppra Xr Levetiracetam Brand 12 $11,831

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$293,357

Of which drugs: $73,028

Medicare patients

653

Average age 75

Services billed

16,943

378 women, 275 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 40%
Diabetes 33%
Depression 29%
Atrial fibrillation 25%
Alzheimer's or dementia 22%
Chronic kidney disease 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 20 13,400 $65,742

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZAVZPRET
$280 — —
UBRELVY
$272 54 —
NURTEC ODT
$262 24 —
QULIPTA
$257 91 —
AJOVY
$174 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

1,598 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record